Table 2.
Correlations of thrombin generation parameters vs. DOAC concentrations or the VKA-INR as measured for patients on chronic anticoagulation. Peak + trough DOAC concentrations were included in this analysis. the VKA-INR, international normalized ratio measured for patients on VKAs. * Based on the linear regression line (DOAC concentration vs. thrombin potential, ETP).
| Thrombin Generation Assay Parameters vs. DOAC Concentrations | ETP Value (95% CI) Corresponding to DOAC Concentration of * | |||
|---|---|---|---|---|
| Lag time (minutes) | Rho | p value | 400 ng/mL | 20 ng/mL |
| DOACs (all) | 0.70 | <0.001 | ||
| Apixaban | 0.48 | <0.001 | ||
| Rivaroxaban | 0.69 | <0.001 | ||
| Edoxaban | 0.82 | <0.001 | ||
| Time-to-peak (minutes) | ||||
| DOAC (all) | 0.66 | <0.001 | ||
| Apixaban | 0.47 | <0.001 | ||
| Rivaroxaban | 0.71 | <0.001 | ||
| Edoxaban | 0.83 | <0.001 | ||
| Peak-thrombin (nM) | ||||
| DOAC (all) | −0.67 | <0.001 | ||
| Apixaban | −0.63 | <0.001 | ||
| Rivaroxaban | −0.73 | <0.001 | ||
| Edoxaban | −0.76 | <0.001 | ||
| Endogenous thrombin potential (nMxmin) | ||||
| DOAC (all) | −0.58 | <0.001 | 914 (802–1026) | 2054 (1492–2166) |
| Apixaban | −0.47 | <0.001 | 1278 (1140–1416) | 2038 (1.900–2176) |
| Rivaroxaban | −0.65 | <0.001 | 473 (250–696) | 1993 (1770–2216) |
| Edoxaban | −0.57 | <0.001 | 867 (662–1072) | 2007 (1802–2212) |
| Thrombin generation assay parameters vs. the VKA-INR | ||||
| Lag time | 0.30 | 0.08 | ||
| Time-to-peak | 0.31 | 0.08 | ||
| Peak-thrombin | −0.53 | <0.01 | ||
| Endogenous thrombin potential | −0.51 | <0.01 | ||